ABCG2 and breast carcinoma: Moreover, recent clinical investigations have demonstrated that both ABCG2 expression levels and genotypic variants are predictive of disease progression and treatment response in breast carcinoma [27,28], glioma [29], hepatoma [30], lymphoma [31,32], nonpapillary renal cell carcinoma [33], and Non-Small Cell Lung Cancer [34].